Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the clinical trial application (CTA) for combination therapy with its self-developed izalontamab brengitecan (BL‑B01D1 / iza‑bren) — described by the company as a first-in-class, new-concept, and the world’s first and only approved EGFR×HER3 bispecific antibody-drug conjugate (ADC) — has been approved by China’s National Medical Products Administration (NMPA). The trial will evaluate iza‑bren in combination with radiotherapy for the treatment of locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) and other solid tumors.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Clinical trial application (CTA) approved |
| Product | Izalontamab brengitecan (BL‑B01D1 / iza‑bren) – EGFR×HER3 bispecific ADC |
| Trial Design | Iza‑bren in combination with radiotherapy |
| Target Population | Locally advanced unresectable HNSCC and other solid tumors |
| Announcement Date | 12 Oct 2026 |
| Trial Details | Phase, sites, and enrollment plans not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Izalontamab brengitecan (BL‑B01D1 / iza‑bren), self-developed by Sichuan Biokin.
- Modality: First-in-class, new-concept bispecific antibody-drug conjugate (ADC) — per the company, the world’s first and only approved EGFR×HER3 bispecific ADC.
- Dual Targets: Simultaneously engages EGFR and HER3, two receptor tyrosine kinases co-expressed across multiple epithelial cancers and implicated in signaling redundancy and resistance.
- ADC Rationale: Dual-receptor engagement is designed to broaden tumor targeting and internalization, delivering the cytotoxic payload to tumors expressing either or both antigens. (Payload and linker details were not elaborated in the announcement.)
- New Combination Axis: The approved trial pairs the ADC with radiotherapy, extending iza‑bren’s development into loco-regional combination treatment of locally advanced disease.
Clinical & Regulatory Progress – Iza‑Bren Portfolio
| Program | Status |
|---|---|
| Recurrent or metastatic nasopharyngeal carcinoma (NPC) | NMPA marketing approval granted |
| Recurrent or metastatic esophageal squamous cell carcinoma (ESCC) | NMPA marketing approval granted |
| Locally advanced or metastatic triple-negative breast cancer (TNBC) | NDA accepted by the Center for Drug Evaluation (CDE) |
| Locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) | Interim analysis successfully met primary endpoint |
| HR+/HER2‑ breast cancer | Interim analysis successfully met primary endpoint |
| Locally advanced unresectable HNSCC + radiotherapy | CTA approved (this announcement) |
Across the portfolio, two approved indications, one accepted NDA, and two positive interim analyses span five tumor types — a breadth uncommon for a single ADC asset. Specific endpoint definitions, trial data, and timelines for the pending programs were not disclosed.
Disease & Treatment Context – Locally Advanced HNSCC
- HNSCC Burden: Head and neck squamous cell carcinoma comprises tumors of the oral cavity, pharynx, and larynx; a substantial share of patients present with locally advanced disease that is unresectable or would require mutilating surgery.
- Radiotherapy Backbone: Definitive radiotherapy (with or without systemic agents) is a cornerstone of curative-intent treatment for locally advanced HNSCC, yet locoregional failure remains a central problem.
- Combination Rationale: Radiotherapy and ADCs act through complementary mechanisms — radiation-driven tumor cell damage alongside targeted cytotoxic payload delivery — providing the scientific basis for evaluating iza‑bren with radiotherapy in this setting. (General domain rationale; combination-specific data were not disclosed.)
- EGFR Biology in HNSCC: EGFR overexpression is a hallmark of squamous cell carcinomas of the head and neck, supporting the target relevance of an EGFR×HER3 bispecific ADC in this tumor type.
Market Impact & Outlook
- From Metastatic to Locally Advanced: The CTA approval extends iza‑bren’s development from recurrent/metastatic settings into curative-intent, locally advanced disease — a substantially larger treatment population if successful.
- Multi-Indication Commercial Momentum: With NPC and ESCC approvals already secured in China, a TNBC NDA under CDE review, and positive interim analyses in EGFR-mutated NSCLC and HR+/HER2‑ breast cancer, Sichuan Biokin is building a multi-franchise commercial platform around a single ADC.
- Differentiated Class Position: As the world’s first and only approved EGFR×HER3 bispecific ADC, iza‑bren occupies a distinct niche versus single-target ADCs in a rapidly crowded conjugate landscape.
- Competitive Landscape: Bispecific ADCs are an emerging global race; iza‑bren’s approved-marketing status in two indications provides an execution head start while combination strategies broaden its reach.
- Next Steps: Initiation of the iza‑bren plus radiotherapy trial, CDE review of the TNBC NDA, and advancement of the NSCLC and breast cancer programs; timelines were not detailed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding izalontamab brengitecan (BL‑B01D1 / iza‑bren), including the radiotherapy combination trial in locally advanced unresectable HNSCC, the pending TNBC NDA review, and further indication expansions. CTA approval permits trial conduct but does not guarantee approval of any new indication. Actual results may differ due to risks including clinical trial outcomes, safety profile in combination with radiotherapy, regulatory review, and competitive dynamics.-Fineline Info & Tech
